(RS)-2-(4-Fluoro-phenyl)-1-(naphthalene-2-sulfonyl)-pyrrolidine | 298690-32-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (RS)-2-(4-Fluoro-phenyl)-1-(naphthalene-2-sulfonyl)-pyrrolidine
• 英文别名: 2-(4-fluorophenyl)-1-naphthalen-2-ylsulfonylpyrrolidine
• CAS: 298690-32-1
• 化学式: C₂₀H₁₈FNO₂S
• 分子量: 355.433
• InChiKey: HOUSUEJAVYOMOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-(4-氟苯基)吡咯烷 、 2-萘磺酰氯 生成 (RS)-2-(4-Fluoro-phenyl)-1-(naphthalene-2-sulfonyl)-pyrrolidine
  参考文献：
  名称：

  1-arenesulfonyl-2-aryl-pyrrolidine and pyridine derivatives

  摘要：

  本发明揭示了具有代谢型谷氨酸受体配体活性的公式为1-芳烃磺酰基-2-芳基吡咯烷和吡啶衍生物。

  公开号：

  US06284785B1

文献信息

• 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1165510A1

  公开（公告）日：2002-01-02
• US6284785B1
  申请人：——

  公开号：US6284785B1

  公开（公告）日：2001-09-04
• [EN] 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS<br/>[FR] DERIVES DE 1-ARENESULFONYL-2-ARYL-PYRROLIDINE ET DE PIPERIDINE POUR LE TRAITEMENT DES TROUBLES DU SYSTEME NERVEUX CENTRAL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2000058285A1

  公开（公告）日：2000-10-05

  The invention relates to compounds of general formula (I) wherein R1 signifies hydrogen, lower alkyl or hydroxy-lower alkyl; R2 signifies furyl, thienyl, pyridyl or phenyl, which is optionally substituted by 1 to 3 substituents, selected from lower alkyl, lower alkoxy, halogen, cyano, CF¿3? or -N(R?4)¿2; R3 signifies naphthyl or phenyl, which is optionally substituted by 1 to 3 substituents, selected from lower alkyl, lower alkoxy, halogen, acetyl, cyano, hydroxy-lower alkyl, -CH¿2?-morpholin-4-yl, lower alkyl-oxy-lower alkyl, lower alkyl-N(R?4)¿2 or CF3; R4 signifies, independently from each other, hydrogen or lower alkyl, with the exception of (RS)-2-phenyl-1-(toluene-4-sulfonyl)-pyrrolidine and (RS)-1-(toluene-4-sulfonyl)-2-p-tolyl-pyrrolidine as well as their pharmaceutically acceptable salts. The compounds described above are metabotropic glutamate receptor antagonists or agonists and therefore useful in the treatment of corresponding CNS disorders.